Unknown

Dataset Information

0

TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer.


ABSTRACT: •There is a lack of prospective level I evidence for the use of PBT for most adult cancers including oropharyngeal squamous cell carcinoma (OPSCC).•TORPEdO is the UK's first PBT clinical trial and aims to determine the benefits of PBT for OPSCC.•Training and support has been provided before and during the trial to reduce variations of contouring and radiotherapy planning.•There is a strong translational component within TORPEdO. Imaging and physics data along with blood, tissue collection will inform future studies in refining patient selection for IMPT.

SUBMITTER: Thomson DJ 

PROVIDER: S-EPMC9702982 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer.

Thomson David J DJ   Cruickshank Clare C   Baines Helen H   Banner Russell R   Beasley Matthew M   Betts Guy G   Bulbeck Helen H   Charlwood Frances F   Christian Judith J   Clarke Matthew M   Donnelly Olly O   Foran Bernadette B   Gillies Callum C   Griffin Clare C   Homer Jarrod J JJ   Langendijk Johannes A JA   Lee Lip Wai LW   Lester James J   Lowe Matthew M   McPartlin Andrew A   Miles Elizabeth E   Nutting Christopher C   Palaniappan Nachi N   Prestwich Robin R   Price James M JM   Roberts Clare C   Roe Justin J   Shanmugasundaram Ramkumar R   Simões Rita R   Thompson Anna A   West Catharine C   Wilson Lorna L   Wolstenholme Jane J   Hall Emma E  

Clinical and translational radiation oncology 20221121


•There is a lack of prospective level I evidence for the use of PBT for most adult cancers including oropharyngeal squamous cell carcinoma (OPSCC).•TORPEdO is the UK's first PBT clinical trial and aims to determine the benefits of PBT for OPSCC.•Training and support has been provided before and during the trial to reduce variations of contouring and radiotherapy planning.•There is a strong translational component within TORPEdO. Imaging and physics data along with blood, tissue collection will i  ...[more]

Similar Datasets

| S-EPMC5779856 | biostudies-literature
| S-EPMC3536640 | biostudies-literature
| S-EPMC8349568 | biostudies-literature
| S-EPMC9894336 | biostudies-literature